Truist Securities maintained its Hold recommendation on agilon health Inc. shares on Monday, assigning a price target of $112.00 while citing the company’s 881% gain over the past six months.
The stock last traded at $95.92, implying a 17% upside to the analyst’s target. InvestingPro’s fair-value estimate stands at $136.88, suggesting potential undervaluation relative to Truist’s view.
Truist hosted agilon health executives for a non-deal roadshow in New York the prior week, where management expressed confidence in optimizing core operations through 2027 and returning to disciplined market expansion in 2028.
Second-quarter 2026 results exceeded expectations, with earnings per share of $1.04, surpassing the Wall Street consensus of $0.08. Revenue reached $1.49 billion, above the projected $1.44 billion. The company subsequently upgraded its full-year outlook following the results.
Jailendra Singh of Truist Securities reiterated the Hold rating, reflecting a balanced view amid the stock’s sharp rally.
